Call Us

AI Factory

N/VISNIUM AI

Revolutionizing Innovation Through Advanced AI Technology

Welcome to the future of innovation. N/VISNIUM AI transforms technology companies by integrating artificial intelligence into core business functions. Our comprehensive AI solutions are designed to reduce operational costs, streamline processes, and optimize decision-making across our portfolio of AI Factory Companies.

Through strategic AI implementation, we enable companies to scale efficiently, expand globally, and capture market opportunities that would otherwise remain out of reach. Our approach fundamentally reimagines how modern technology companies achieve sustainable growth and market leadership.

THE N/VISNIUM AI ADVANTAGE

N/VISNIUM AI transforms company operations through advanced artificial intelligence integration. By embedding sophisticated AI systems into our nanotechnology firms, we’re reshaping how these companies develop, manufacture, and deliver breakthrough solutions that address critical global challenges.

Our portfolio companies are developing innovative nanotechnology platforms designed to address significant gaps in existing markets. Strategic AI integration enables these firms to achieve operational excellence, accelerate product development cycles, and significantly enhance profitability through optimized processes and data-driven decision making.

Valuable Intellectual Property Portfolio

N/VISNIUM AI portfolio companies are building intellectual property portfolios that include patent-pending technologies, trademark applications, and proprietary innovations. This comprehensive IP strategy delivers three strategic advantages: establishing competitive market protection, providing robust legal safeguards for our innovations, and enhancing appeal to institutional investors and strategic partners.

REVOLUTIONARY PORTFOLIO COMPANIES

CARBON FIBER MAX

The Carbon Fiber Revolution

A High-Performance Lightweight Alternative to Traditional Carbon Fiber

Carbon Fiber Max is a true carbon fiber alternative at a superior price point. Since carbon fiber is scarce and production cannot keep up with demand, Carbon Fiber Max is designed to fill this void with competitive performance characteristics and significant manufacturing advantages.

Revolutionary Composition:

  • Advanced Formula: Blend of tungsten nanotubes, carbon nanotubes, and nylon (80% nylon, 10% carbon nanotubes and 10% tungsten nanotubes)
  • Superior Manufacturing: Can be injection molded, unlike carbon fiber
  • Multiple Forms: Available as fiber, pellets, fabric, and finished parts

Performance Advantages:

  • Higher Temperature Capabilities: Engineered for higher temperature performance than standard nylon
  • Impact Resistance / Toughness: Strong mechanical properties suitable for a wide range of demanding applications
  • Injection Moldable: Creates complex parts impossible with carbon fiber
  • Abundant Supply: Unlike scarce carbon fiber, can meet or exceed demand
  • Waterproof: Forces moisture to surface for evaporation
  • Corrosion Resistant: Exceptional resistance to harsh environments

Target Industries:

  • Automotive: Formula 1, NASCAR, high-end vehicle components
  • Aerospace: Aircraft components, superior strength-to-weight ratio
  • Military: Rockets, aircraft components, defense applications
  • Sporting Goods: Tennis rackets, golf clubs, athletic equipment
  • Wind Energy: Turbine blades 25% lighter than fiberglass alternatives

 

Market Opportunity: The combined global carbon fiber and advanced composites market represents a $24 billion industry, with demand driven by mass-produced applications across automotive, aerospace, defense, and industrial sectors. Carbon Fiber Max is patent pending, with pilot production underway, and is being positioned to compete in this growing market.

Visit our website: https://carbonfibermax.com/

Market Opportunity:

The global MRSA drug treatment market was valued at approximately $4 billion in 2024 and is projected to reach $5–7 billion by 2033, driven by rising antibiotic resistance, expanding ICU populations, and the absence of new treatment options. The bacteriophage therapy market is projected to reach $1 billion by 2030, growing at over 17% annually — the fastest-growing segment within the global antimicrobial resistance market. Government agencies and major healthcare investors have collectively deployed over $130 million into CRISPR-enhanced phage therapy platforms since 2023, validating both the science and the commercial opportunity. LyticGen Pharmaceuticals™ is patent-pending, advancing through preclinical development, and is being positioned to compete in this critical and rapidly growing market.

Visit our website: https://www.LyticGen.com 

LYTICGEN PHARMACEUTICALS™

The Bacteriophage Revolution

A CRISPR-Enhanced Bacteriophage Therapeutic Platform for Antibiotic-Resistant Infections

LyticGen Pharmaceuticals is developing VDX-10 — a next-generation, CRISPR-engineered bacteriophage therapeutic designed to fight bacterial infections that antibiotics can no longer stop. As antibiotic resistance accelerates globally and the pipeline for new antibiotics remains critically thin, LyticGen’s platform is engineered to fill this void with a precision biological agent that operates through an entirely different mechanism than any existing drug.

Proprietary Two-Stage Platform:

  • Systematic Progenitor Selection: Candidate bacteriophages are screened in controlled isolation chambers to identify the phage with the highest kill rate against target S. aureus strains — ensuring only the most effective progenitor advances
  • CRISPR Genome Enhancement: The selected progenitor is enhanced using CRISPR/Cas9 gene editing to insert sequences that accelerate replication, expand host range across clinical isolates, and disable bacterial anti-phage defense mechanisms
  • Lead Candidate: VDX-10: Patent-pending CRISPR-enhanced bacteriophage targeting Staphylococcus aureus, including MRSA and MSSA, for MRSA bacteremia and ventilator-associated pneumonia (VAP)

Therapeutic Advantages:

  • Precision Targeting: Engineered to destroy S. aureus with specificity that leaves healthy tissue and the body’s natural microbiome completely untouched — no broad-spectrum disruption
  • Overcomes Antibiotic Resistance: Operates through a fundamentally different mechanism than antibiotics — no cross-resistance; bacteria that have defeated vancomycin and daptomycin remain susceptible to phage attack
  • Superior to Natural Phage Therapy: CRISPR enhancement delivers estimated 2–4× faster kill speed, 3–5× broader host range, and engineered resistance to bacterial immune defenses that defeat unmodified phages
  • Biofilm Penetration: Designed for enhanced penetration of bacterial biofilms — the primary cause of treatment failure in device-associated and catheter-related MRSA infections
  • No Nephrotoxicity: Unlike vancomycin, which carries significant kidney toxicity risk requiring therapeutic drug monitoring, phage therapy has no renal toxicity mechanism
  • Scalable Manufacturing: Produced in bioreactors and purified to pharmaceutical standards — designed for consistent, scalable production unlike patient-specific natural phage preparations

 

Target Indications and Markets:

  • MRSA Bacteremia: Bloodstream infections with 15–50% 30-day mortality despite vancomycin — the highest unmet need in hospital-acquired infectious disease
  • Ventilator-Associated Pneumonia (VAP): aureus VAP in ICU patients; VDX-10 formulated for nebulized aerosol delivery directly to the lung
  • Device-Associated Infections: Catheter-related and implant-associated biofilm infections — a growing and difficult-to-treat category as medical device use expands
  • Hospital & Academic Medical Centers: S. hospital systems, academic medical centers, and ICU-based infectious disease programs as initial commercial access pathway
  • Government and Defense: BARDA and DoD anti-infective programs — MRSA is a priority pathogen for both civilian hospital and military field medicine applications